Impilo vs PurposeMed: Revenue, Funding & Team Size Compared
Impilo generates $14.3M in revenue; PurposeMed generates $51.4M. PurposeMed is 3.6× bigger than Impilo by revenue. The table below compares Impilo and PurposeMed on funding, valuation, customers, team size and headquarters — every figure GetLatka has verified for each company.
| Company |  ImpiloThis company |  PurposeMed |
|---|---|---|
| Revenue | $14.3M | $51.4M |
| Team size | 59 | 138 |
| Founded | 2020 | 2019 |
| HQ | Philadelphia, United States | Calgary, Canada |
Want the full dataset? GetLatka tracks revenue, funding and team history for thousands of SaaS companies, with charts, growth rates and founder interviews.
Impilo at a glance
Impilo generates $14.3M in revenue with 59 employees, headquartered in Philadelphia, United States.
- Revenue
- $14.3M
- Team size
- 59
- Founded
- 2020
Impilo is a developer of digital health operating systems aimed at improving the infrastructure underlying remote healthcare. The company focuses on remote patient monitoring and virtual care programs, simplifying quality support for…
PurposeMed at a glance
PurposeMed generates $51.4M in revenue with 138 employees, headquartered in Calgary, Canada.
- Revenue
- $51.4M
- Team size
- 138
- Founded
- 2019
PurposeMed is a health technology company focused on improving access to complex care for underserved communities by re-imagining healthcare. They provide accessible and specialized healthcare services, connecting patients with clinicians…
Other Impilo alternatives
Impilo competes with more than the companies on this page. Browse the full alternative lists to compare revenue, funding and team size across the category.
Impilo vs PurposeMed: frequently asked questions
Is Impilo or PurposeMed bigger?
PurposeMed is the bigger company by revenue, at $51.4M against $14.3M for Impilo.
How much revenue does Impilo make?
Impilo generates $14.3M in annual revenue with a team of 59.
How much revenue does PurposeMed make?
PurposeMed generates $51.4M in annual revenue with a team of 138.